these-three

3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year

Gilead Sciences’ (NASDAQ: GILD) blockbuster launches of the hepatitis C drugs Sovaldi and Harvoni resulted in its revenue jumping 122% in 2014, but with Gilead Sciences facing tough comparisons this year, these three big-cap biotech stocks may be in better positions to see their shares climb in 2015http://www.fool.com/investing/general/2015/03/01/3-big-cap-biotechs-that-could-trounce-gilead-scien.aspx

Source:

3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year

See which stocks […]